06/10/2026
Everyone’s talking about the 28% reduction in WEIGHT. Nobody’s talking about how they got there.
The retatrutide phase 3 results are out, the last stage before approval. On the top dose, 12 mg a week, people lost 28.3% of their body weight on average over 80 weeks.
We already knew it beat Mounjaro and Ozempic. But okay, good to finally see the undeniable proof.
Now read how it was run.
12 mg every week. Some advice to eat well and move more.
No calorie target. No nutrition plan. No resistance training programme. On people with an average BMI of 40.
They know habits and behaviours massively change the result. They chose not to include support…
The lowest dose, 4 mg, still averaged 19%. A third of the dose. Two thirds of the result < this is better, but it’s less profitable…
As far as I’m concerned, this proves these trials aren’t just about safety. They’re the marketing, and they set the licensed dose. Once it’s approved, expect people pushed up to 12 mg fast. Which, guess what, is the most expensive dose, and the one that keeps people most reliant.
And with weight loss this quick, 25 to 40% of what comes off is lean mass. Come off it with nothing learned and the weight comes back. The muscle doesn’t. That’s much more metabolically unhealthy.
Now follow the money. The company behind retatrutide and Mounjaro also makes the drugs for when your metabolic health gets worse. Their diabetes drug Trulicity alone brought in $4.3bn in 2025. Two thirds of the FDA’s drug review budget is paid by drug company fees. And they’re in court right now trying to get retatrutide classed as a biologic: 12 years where nobody else can make it.
I’ve spoken to hundreds of people on Ozempic and Mounjaro through their doctor. None were given support on training, nutrition or habits. Almost all were told to go up the dose. And when people stop, two thirds of the weight comes back within a year.
The drug is a tool. It works. We’re not saying don’t use it. We’re saying your habits, your food and your training decide the result, so don’t hand all of it to a company that earns more the more you need it.
Sources on every slide. Send it to someone on a jab.